🔎 Trials Near Me

Početna › Rabdomiosarkom › Texas

Kliničke studije za Rabdomiosarkom u državi Texas

9 studija za Rabdomiosarkom traži sudionike na lokacijama u državi Texas.

Gradovi u državi Texas

Službeni tekst studije (engleski)

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

  • University of Texas - MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
24 Months – 18 Years · Oba spola · Ažurirano 25. ruj 2026. · NCT06441331

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Children's Medical Center, Dallas
U tijeku regrutacijaFaza 1/2
Do 30 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT06541262

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • i još 2
U tijeku regrutacijaFaza 3
Do 50 godina · Oba spola · Ažurirano 25. kol 2026. · NCT07466316

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

  • Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. kol 2026. · NCT04715191

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 1/2
Od 1 do 30 godina · Oba spola · Ažurirano 22. srp 2026. · NCT06721689

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

  • Cook Children's Medical Center, Fort Worth
U tijeku regrutacijaFaza 2
Do 22 godina · Oba spola · Ažurirano 15. lip 2026. · NCT06023641

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

  • The University of Texas Southwestern Medical Center, Dallas
  • Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 1/2
6 Months – 30 Years · Oba spola · Ažurirano 2. lip 2026. · NCT04796012

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

  • Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 1
Od 1 do 25 godina · Oba spola · Ažurirano 22. sij 2026. · NCT04995003

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

  • Houston Methodist Hospital, Houston
U tijeku regrutacijaFaza 1
Do 21 godina · Oba spola · Ažurirano 3. stu 2025. · NCT06198296

Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.